Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck KGaA, Cancer Research U.K., Cardiff University, The Institute of Cancer Research deal

Merck's Merck Serono S.A. unit received rights to develop preclinical molecules against the Wnt pathway to

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE